Objectives: Understand the use of retinoids in dermatology.
Learn about a novel micro encapsulation technology-calcium hydroxyapatite hydroxysomes for retinaldehyde stability, delivery and efficacy.
Introduction: Retinoic acid is a cornerstone of dermatology therapy for the treatment of acne, signs of skin aging, discoloration and pore size. Irritation limits its practical use. A study of a novel encapsulated retinal was performed to ascertain stability of the molecule, performance and reduction in scaliness and dryness compared to Adapaline, a third generation retinoid.
Materials / method: Female subjects of mixed ethnicities used calcium hydroxyapatite encapsulated retinaldehyde .075%, daily for 8 weeks. Efficacy was measured and skin replica analysis was performed.
Female subjects then used calcium hydroxyapatite encapsulated retinaldehyde .075% compared to Adapaline .1% for a 12 week study. Efficacy and side effects were measured.
Results: 8 weeks study revealed visible overall improvement in firmness, fine lines, wrinkles, and dyschromia. Skin replica analysis showed 25% reduction in crows feet.
12 week study of encapsulated Retinal vs. Adapaline showed similar statistically significant anti aging efficacy yet the Retinal was more tolerable with 75% of Adapaline users experiencing scaling and 65% experiencing dryness.
Conclusion: Hydroxysomes, made of calcium hydroxyapatite act as a micro carrier of retinaldehyde. This novel encapsulation stabilizes retinal, allows slow extended release for better bioavailability and attenuating irritation. Calcium also strengthens the skin barrier. Anti aging results were comparable to Adapaline without the irritation and increased compliance.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
是
请注明日期: Active status
和审阅情况: Owner of Rodan and Fields, and research and development lab
这项工作的完成感谢以下机构的支持: Rodan and Fields, LLC